Aussie Drug Delivery Company PolyActiva Raises AU$9.2 Mil In Series B For Glaucoma Candidate
This article was originally published in PharmAsia News
Executive Summary
With AU$9.2 million in Series B financing, Australian drug delivery company prepares Phase II trial for levofloxacin antibiotic delivery system.